Abstract
Cells are the fundamental structure composing our bodies and hence cellular decline (called senescence) contributes to ageing. Endogenous and exogenous stresses may induce cellular senescence. Stressors are mainly macromolecule damage events, which include: shortening of chromosome telomeres; non-telomeric DNA damage; excessive mitogenic signals, which may cause DNA damage; and non-genotoxic stress, such as perturbations to chromatin organization.
For many years the analysis of chromatin perturbation as a leading event in triggering senescence has been overlooked. Now, it is well recognized that chromatin DNA packaging is not immune to the ravages of time. All eukaryotes experience changes in chromatin organization and gene-expression patterns as they age. This can be due to perturbation in the function of chromatin modifiers. In this review we will discuss the role in the senescence process of the different types of chromatin modifiers, such as the ATP-dependent chromatin remodelling complexes, the enzymes that covalently modify histone tails and proteins involved in DNA methylation.
Keywords: ATP-dependent chromatin remodeling, histone modification, DNA methylation, heterochromatin, euchromatin, ageing
Current Pharmaceutical Design
Title:Chromatin Modification and Senescence
Volume: 18 Issue: 13
Author(s): Giovanni Di Bernardo, Marilena Cipollaro, Umberto Galderisi
Affiliation:
Keywords: ATP-dependent chromatin remodeling, histone modification, DNA methylation, heterochromatin, euchromatin, ageing
Abstract: Cells are the fundamental structure composing our bodies and hence cellular decline (called senescence) contributes to ageing. Endogenous and exogenous stresses may induce cellular senescence. Stressors are mainly macromolecule damage events, which include: shortening of chromosome telomeres; non-telomeric DNA damage; excessive mitogenic signals, which may cause DNA damage; and non-genotoxic stress, such as perturbations to chromatin organization.
For many years the analysis of chromatin perturbation as a leading event in triggering senescence has been overlooked. Now, it is well recognized that chromatin DNA packaging is not immune to the ravages of time. All eukaryotes experience changes in chromatin organization and gene-expression patterns as they age. This can be due to perturbation in the function of chromatin modifiers. In this review we will discuss the role in the senescence process of the different types of chromatin modifiers, such as the ATP-dependent chromatin remodelling complexes, the enzymes that covalently modify histone tails and proteins involved in DNA methylation.
Export Options
About this article
Cite this article as:
Giovanni Di Bernardo, Marilena Cipollaro, Umberto Galderisi , Chromatin Modification and Senescence, Current Pharmaceutical Design 2012; 18 (13) . https://dx.doi.org/10.2174/138161212799859693
DOI https://dx.doi.org/10.2174/138161212799859693 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Runx2/Cbfa1: A Multifunctional Regulator of Bone Formation
Current Pharmaceutical Design Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer
Current Chemical Biology Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Emerging Anabolic Treatments in Osteoporosis
Current Drug Safety Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery High-Content Analysis of Kinase Activity in Cells
Combinatorial Chemistry & High Throughput Screening Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
Current Cancer Drug Targets Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
Current Cancer Drug Targets Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Cancer Genetics and Drug Discovery in Mice
Letters in Drug Design & Discovery Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets